659 related articles for article (PubMed ID: 19491013)
1. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
2. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
3. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
[TBL] [Abstract][Full Text] [Related]
4. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
5. Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug.
Silva M; Ricelli NL; El Seoud O; Valentim CS; Ferreira AG; Sato DN; Leite CQ; Ferreira EI
Arch Pharm (Weinheim); 2006 Jun; 339(6):283-90. PubMed ID: 16688684
[TBL] [Abstract][Full Text] [Related]
6. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
7. Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis.
Corrêa MF; Fernandes JP
Curr Protein Pept Sci; 2016; 17(3):213-9. PubMed ID: 26427385
[TBL] [Abstract][Full Text] [Related]
8. The curious characteristics of pyrazinamide: a review.
Zhang Y; Mitchison D
Int J Tuberc Lung Dis; 2003 Jan; 7(1):6-21. PubMed ID: 12701830
[TBL] [Abstract][Full Text] [Related]
9. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
10. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Scorpio A; Nikaido H; Sun Z
J Bacteriol; 1999 Apr; 181(7):2044-9. PubMed ID: 10094680
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of sugar-derived esters, alpha-ketoesters and alpha-ketoamides as inhibitors for Mycobacterium tuberculosis antigen 85C.
Sanki AK; Boucau J; Umesiri FE; Ronning DR; Sucheck SJ
Mol Biosyst; 2009 Sep; 5(9):945-56. PubMed ID: 19668859
[TBL] [Abstract][Full Text] [Related]
12. Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
Rosen BC; Dillon NA; Peterson ND; Minato Y; Baughn AD
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855077
[TBL] [Abstract][Full Text] [Related]
13. Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating Mycobacterium tuberculosis.
Segretti ND; Simões CK; Corrêa MF; Felli VMA; Miyata M; Cho SH; Franzblau SG; Fernandes JPDS
Tuberculosis (Edinb); 2016 Jul; 99():11-16. PubMed ID: 27449999
[TBL] [Abstract][Full Text] [Related]
14. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
Gopal P; Tasneen R; Yee M; Lanoix JP; Sarathy J; Rasic G; Li L; Dartois V; Nuermberger E; Dick T
ACS Infect Dis; 2017 Jul; 3(7):492-501. PubMed ID: 28271875
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
Yamamoto S; Toida I; Watanabe N; Ura T
Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
[TBL] [Abstract][Full Text] [Related]
16. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.
Sayahi H; Pugliese KM; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
Chem Biodivers; 2012 Nov; 9(11):2582-96. PubMed ID: 23161636
[TBL] [Abstract][Full Text] [Related]
17. Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
Njire M; Wang N; Wang B; Tan Y; Cai X; Liu Y; Mugweru J; Guo J; Hameed HMA; Tan S; Liu J; Yew WW; Nuermberger E; Lamichhane G; Liu J; Zhang T
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438933
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
Rajendran V; Sethumadhavan R
J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydro-2H-1,3,5-thiadiazine-5-(4-pyridylcarboxamide)-2-thione derivatives as prodrugs for isoniazid; synthesis, investigations and in vitro antituberculous activity.
Aboul-Fadl T; Hassanin K
Pharmazie; 1999 Apr; 54(4):244-7. PubMed ID: 10234734
[TBL] [Abstract][Full Text] [Related]
20. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.
Yan L; Müller CE
J Med Chem; 2004 Feb; 47(4):1031-43. PubMed ID: 14761205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
